Video
Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses specialty areas experiencing innovative developments in therapies.
Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses specialty areas where innovative developments in therapies are being seen.
Transcript
There’s a lot of innovation within the ALS community, not only from a symptomatic point of view but even from a disease progression point of view. ALS is really lumped into that area of orphan disease. And there’s been a lot of innovation in the orphan disease space with things like ALS, hereditary angioedema, and other "orphan diseases". We at our pharmacy work quite a bit with those particular disease states. The other areas where you’re seeing a lot of innovation and continue to see innovation is in the areas of oncology, rheumatology, and other neurological disease states like MS, tardive dyskinesia. There’s just an explosion in these particular areas in the way therapies are being developed and targeted to treat specific types of those types of diseases.
FDA Grants Orphan Drug Designation to MDL-101 for Congenital Muscular Dystrophy Type 1a